Assist Sirio to sell its subsidiary Qianlin to Pfizer

In January 14, 2016, the world's leading pharmaceutical group Pfizer Inc announced that it has completed the acquisition of China pharmaceutical enterprise - Qianlin Pharmaceutical Co. Ltd which is a wholly owned subsidiary of Sirio and its right of producing and selling Qianlin brand serious products with 100% stake. KW Capital as sell-side FA assisted Sirio Pharmaceutical Co. company to complete the transaction. The project, from tender to delivery, has lasted nine months, which is the largest M & A project done by KW Capital as a sell-side FA so far. Pfizer, a pharmaceutical landmark enterprise and a specialist in mergers and acquisitions, has not hired third-party financial advisers, but is directly executed by its merger and acquisition team, and the negotiation against such powerful counterparties has helped us to exercise and improve our professional skills.